New preclinical drug candidate shows promise in eradicating

A new preclinical drug candidate developed by scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) shows great promise in eradicating the bacteria causing gonorrhea, according to a new publication.

Related Keywords

United States , American , Joel Freundlich , Barry Kreiswirth , David Perlin , Ihor Sawczuk , Emily Henderson , American Society For Microbiology , National Institutes Of Health , World Health Organization , Hackensack Meridian School Of Medicine , Rutgers University , Hackensack Meridian Center , Translational Research , Hackensack Meridian Health , Antimicrobial Agents , American Society , World Health , National Institutes , Clinical Integration , Hackensack Meridian School , Gonorrhea , Laboratory , Bacteria , Chemotherapy , Compound , Drugs , Mh , Reclinical , Research ,